Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.
Saved in:
| Title: | Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease. |
|---|---|
| Authors: | Sabahi Z; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia., Nguyen A; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Wong K; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Li S; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Papa N; Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia., Lim E; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Dear RF; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.; Department of Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Menzies AM; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Wollstonecraft, New South Wales, Australia., Boyle F; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Wollstonecraft, New South Wales, Australia., Antill Y; Department of Medical Oncology, Peninsula Health, Frankston, Victoria, Australia.; Faculty of Medicine and Health Sciences, Monash University, Clayton, Victoria, Australia., Kiely BE; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Campbelltown Hospital, Campbelltown, New South Wales, Australia; and., Forster BC; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Wollstonecraft, New South Wales, Australia., Mak C; Chris O'Brian Lifehouse, Camperdown, New South Wales, Australia., Adams D; Department of Medical Oncology, Campbelltown Hospital, Campbelltown, New South Wales, Australia; and., Pugliano L; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Wollstonecraft, New South Wales, Australia., Spillane A; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Wollstonecraft, New South Wales, Australia., Sharma S; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Hickey A; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Poole A; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Agrawal S; Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia., Khan S; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Ayati N; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Emmett L; Theranostics and Nuclear Medicine Department, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia; louise.emmett@svha.org.au.; Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2025 May 01; Vol. 66 (5), pp. 700-706. Date of Electronic Publication: 2025 May 01. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1535-5667 |
|---|---|
| DOI: | 10.2967/jnumed.124.268896 |
